/CV

CV

CV

$6.71USD↑+5.01%+0.32 today

MARKET CAP

335.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $7

52W RANGE

$3

$15

AI Summary

Stalk

StalkMedium

CV is in a Stage 2 advancing phase with a bullish medium-term bias reinforced by higher highs and higher lows, rising short-term EMAs, and low transition risk. Price is currently extended above key EMAs without a clear pullback, so execution should be deferred into structural support zones rather than pursued on the current extension.

↑167k patients scanned with Capsule Chem Plus, showing robust adoption.
↑AI integration expected to cut wait times and boost workflow efficiency.
↓Net loss of $7.9M in Q3 2025; operating loss widened to $8.4M in Q1 2026.

Full analysis →

Min Company Value

AI View

Min Insiders / Ticker

Hide Automated (10b5-1)

Date Range

Insider Trades2 trades

Date↓	Side	Ticker↕	Insider↕	Role↕	Shares↕	Price↕	Mkt Cap↕	52W High↕	52W Low↕	Value↕	% Chg↕	Rule↕	AI View↕
May 4, 2026	Buy	CV	Douglas Patrick Atkinson	Head of Global Sales	107,357	$0.42	$335.3M	-56.34%	+95.39%	$44.7K	+43.46%	—	Sell Now
Aug 18, 2025	Buy	CV	Rebecca Ann Petersen	Director of Clinical Affairs	24,834	$0.37	$335.3M	-56.34%	+95.39%	$9.1K	+672.28%	—	Sell Now